Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
category_row_disappeared. FY 2025-26 omits other, filed in this company's other years. Absence is not a reported zero.
reporting_boundary_changed. Reporting boundary changed across years: FY 2022-23 Consolidated, FY 2023-24 Consolidated basis, FY 2024-25 Consolidated, FY 2025-26 Consolidated. Year-on-year figures cover different entities.
| Category | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| Plastics including packaging | not filed | not filed | 0 | 0 |
| E-waste | not filed | not filed | 0 | 0 |
| Hazardous waste | not filed | not filed | 0 | 0 |
| Other waste | 0 | 0 | not filed | not filed |
| Total reclaimed | 0 | 0 | 0 | 0 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| Since the Company is engaged in Pharmaceuticals sector, we do not recycle or reuse input materials. | 0.0% | not filed | not filed | not filed |
| Since the Company is engaged in the Pharmaceuticals sector, we do not recycle or reuse input materials | not filed | 0.0% | not filed | not filed |
| NA | not filed | not filed | 0.0% | not filed |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 21002 | Radiopharmaceuticals | 44.57% |
| 21002 | Contract manufacturing operations | 21.19% |
| 21002 | Allergy therapy products | 9.49% |
| 21002 | Solid dosage formulations | 8.66% |
| 21001 | Active pharmaceutical ingredients | 6.81% |
| 72100 | Contract Research and Development Services | 7.89% |
| 46497 | India branded pharmaceuticals | 0.68% |
| 70200 | Management Services | 0.71% |
| 72100 | Proprietary Noval Drugs | — |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2022-23 | Consolidated | 2023-06-30 | 62,81,70,00,000 |
| FY 2023-24 | Consolidated basis | 2024-04-30 | 67,02,90,00,000 |
| FY 2024-25 | Consolidated | 2025-05-31 | 72,34,50,00,000 |
| FY 2025-26 | Consolidated | 2026-02-28 | 82,79,60,00,000 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error